2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In Partnership With:
Conference | ESMO Congress
Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses preliminary findings from an ongoing phase 1/2 trial (NCT05119335) investigating the HIF-2α inhibitor NKT-2152 in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), as well as the potential clinical implications of these data.